RAS testing in metastatic colorectal cancer: Excellent reproducibility amongst 17 Dutch pathology centers

In 2013 the European Medicine Agency (EMA) restricted the indication for anti- EGFR targeted therapy to metastatic colorectal cancer (mCRC) with a wild-type RAS gene, increasing the need for reliable RAS mutation testing. We evaluated the completeness and reproducibility of RAS-testing in the Netherlands. From 17 laboratories, tumor DNA of the first 10 CRC cases tested in 2014 in routine clinical practice was re-tested by a reference laboratory using a custom next generation sequencing panel. In total, 171 CRC cases were re-evaluated for hotspot mutations in KRAS, NRAS and BRAF. Most laborator... Mehr ...

Verfasser: Boleij, Annemarie
Tops, Bastiaan B J
Rombout, Paul D.M.
Dequeker, Elizabeth M.
Ligtenberg, Marjolijn J. L.
van Krieken, J. Han
van Noesel, Carel J M
Scheidel-Jacobse, Karen C.
Kummer, J. A.
Roepman, P.
Prinsen, C.F.M.
van den Berg-van Erp, S. H.M.
van Gorp, J. M.H.H.
Nederlof, Petra M.
Caspers, E.
Dinjens, Winand N M
Beerens, E. C.W.
't Hart, N. A.
van den Brule, Adriaan J. C.
van der Geize, R.
Riemersma, S. A.
van Wezel, T.
Morreau, H.
van Eijk, R.
Jeuken, J. W.M.
Dirkx, A.
Klomp, J.M.
van Blokland, W. T.M.
ter Elst, A.
Schuuring, E.
Diepstra, A.
Heideman, Danielle A. M.
van Grieken, Nicole C. T.
Sie, D.
Dutch RAS EQA Initiative
Dokumenttyp: Artikel
Erscheinungsdatum: 2015
Schlagwörter: Colorectal cancer / Metastasis / Next generation sequencing / Quality control / RAS / Oncology
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27456207
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://dspace.library.uu.nl/handle/1874/357595